First-in-class [ 18 F]-PET radiotracers for GPR39: A platform for noninvasive target engagement imaging in vivo

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Disrupted zinc homeostasis is a hallmark of Alzheimer’s disease. As a key zinc-sensing receptor, GPR39, a G-protein coupled receptor is implicated in neurodegeneration, vascular regulation, and neuropsychiatric disorders, represents an emerging target for molecular imaging. However, the lack of suitable positron emission tomography (PET) radiotracers has limited GPR39 in vivo characterization. Quantitative assessment of GPR39 levels in vivo helps in understanding its role in physiology and pathology. This will facilitate the development of targeted therapeutics and enable real-time monitoring of treatment response in clinical settings. This study introduces [ 18 F]GPR39-2.1 as a PET radiotracer specificity towards GPR39. [ 18 F]GPR39-2.1 exhibited excellent serum stability with negligible radio-metabolite formation. In vitro cell uptake studies showed reduced tracer uptake (55–70%) upon pharmacological blockade. PET imaging demonstrated rapid brain uptake and efficient with blood–brain barrier penetration, followed by gradual washout. Blockade studies in rats revealed significant reductions in brain uptake (up to ∼90%, **** p <0.0001), consistent across multiple brain regions. Receptor specificity was further validated in GPR39 knockout mice, which exhibited reduced brain uptake of 76% (** p <0.002) and 90% (*** p <0.0002) in both PET imaging and biodistribution studies, respectively. Moreover, significantly lower brain uptake observed in 5xFAD transgenic mice (PET imaging: 40%, *** p <0.0002 and biodistribution: 77%, ** p <0.002) indicates sensitivity of [ 18 F]GPR39-2.1 to disease-associated changes of GPR39. Biodistribution analysis revealed favorable pharmacokinetics. Autoradiography studies further confirmed the specificity of [ 18 F]GPR39-2.1 towards GPR39, corroborating PET imaging and biodistribution studies. These findings establish [ 18 F]GPR39-2.1 as a highly specific, stable, and brain-penetrant PET radiotracer for imaging GPR39 in vivo . This work supports the utility of [ 18 F]GPR39-2.1 as a noninvasive molecular imaging agent for neurological and systemic diseases associated with GPR39 dysregulation. Overall, this work establishes a translational framework for investigating GPR39 biology and facilitates its clinical translation as a diagnostic and therapeutic target through [ 18 F]GPR39-2.1.

Article activity feed